Moss Genomics to list on CSE

Photo of author

By CPE News

CPE News Brief (6.17.2022) – Moss Genomics Inc. has filed preliminary long form non-offering prospectus British Columbia Securities Commission (BCSC) to become a reporting issuer.

No securities are being offered pursuant to this prospectus.

Concurrently with the filing of the prospectus, Moss Genomics intends to apply to list its common shares on the Canadian Securities Exchange (CSE).

Moss Genomics Inc. is an emerging consumer genomics company with a head office in Vancouver and operations in San Diego, California. The company intends to be a disrupter in the consumer healthcare space offering personalized health, anti-aging and wellness offerings guided by genomic, microbiome, and epigenome data.

Karl Cahill, founder and CEO & Director, is Moss Genomics’ only 10% beneficial shareholder controlling 5 million common shares (11.34%).

photo credit: Moss Genomics